CGEM Company Profile and Key Details

Q: Who are the executives of CGEM?

Ms. Rose WeldonSenior Vice President of CommunicationsDr. Corinne Savill Ph.D.Chief Bus. OfficerMr. Nadim AhmedPres, Chief Executive Officer & DirectorMr. Jeffrey TrigilioChief Financial Officer & TreasurerDr. Jennifer Michaelson Ph.D.Chief Devel. OfficerMr. Steve AndreChief HR OfficerMs. Kerry WhalenSenior Director of Preclinical & Early Devel.Mr. Kevin A. JohnstonChief Technical Operations OfficerDr. Patrick A. Baeuerle Ph.D.Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory BoardDr. Jeffrey Jones M.B.A., M.D., M.P.H.Chief Medical OfficerMs. Jacquelyn L. Sumer J.D.Chief Legal Officer, Chief Compliance Officer & Corporation Sec.

NASDAQ : CGEM

Cullinan Therapeutics

$20.54

0.14+0.69%

At Close 4:00 PM

69.96

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Cullinan Therapeutics, Inc. (CGEM) stock surged +0.69%, trading at $20.54 on NASDAQ, up from the previous close of $20.40. The stock opened at $20.38, fluctuating between $19.64 and $20.70 in the recent session.

Stock Snapshot

20.4

Prev. Close

1.26B

Market Cap

19.64

Day Low

-6.63

P/E Ratio

-3.1

EPS (TTM)

-3.14

Cash Flow per Share

20.38

Open

61.46M

Number of Shares

20.7

Day High

61.03%

Free Float in %

10.6

Book Value

1.06M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 15, 2026	20.38	20.71	19.64	20.54	1.06M
Sep 14, 2026	18.55	20.93	18.51	20.40	1.42M
Sep 11, 2026	21.16	21.34	20.10	20.59	1.09M
Sep 10, 2026	20.99	21.22	20.50	21.00	805.64K
Sep 09, 2026	21.30	21.80	21.08	21.31	1.28M
Sep 08, 2026	21.61	22.41	21.28	21.69	953.2K
Sep 04, 2026	21.88	22.30	21.77	22.09	562.12K
Sep 03, 2026	22.39	22.68	21.65	22.16	524.12K
Sep 02, 2026	21.88	22.79	21.75	22.33	769.63K
Sep 01, 2026	21.80	22.07	21.55	21.79	546.14K
Aug 31, 2026	21.50	22.23	21.34	22.07	682.53K
Aug 28, 2026	22.60	22.88	21.57	21.70	630.05K
Aug 27, 2026	22.55	22.96	22.19	22.60	471.91K
Aug 26, 2026	22.66	23.19	22.42	22.85	683.33K
Aug 25, 2026	22.16	23.06	22.16	22.95	519.25K
Aug 24, 2026	21.62	22.37	21.16	21.82	617.29K
Aug 21, 2026	21.72	22.11	21.40	21.68	758.08K
Aug 20, 2026	22.14	22.25	21.02	21.38	902.53K
Aug 19, 2026	21.48	22.54	21.22	22.52	706.84K
Aug 18, 2026	20.23	21.20	19.99	20.84	595.06K

Contact Details

Cambridge, MA 02142

United States

https://cullinantherapeutics.com 617 410 4650

About Company

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Stock Peers

ARGX

-10.78-1.09%

argenx SE$979.76 REGN

-19.63-2.47%

Regeneron Pharmaceuticals, Inc.$774.11 MDGL

-16.8-3.11%

Madrigal Pharmaceuticals, Inc.$523.26 VRTX

-4.88-0.94%

Vertex Pharmaceuticals Incorporated$514.63 UTHR

-2.35-0.47%

United Therapeutics Corporation$500.35 ONC

-7.33-2.07%

BeOne Medicines AG$346.50 KRYS

-3.35-0.99%

Krystal Biotech, Inc.$336.68 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-17.65-5.34%

Praxis Precision Medicines, Inc.$312.90 LGND

-3.67-1.31%

Ligand Pharmaceuticals Incorporated$276.98

Company Overview

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) closed at $20.54 USD, gaining $0.14 (0.69%) from the previous close of $20.40. The stock is currently mid-range between its 52-week high and low $5.68 and $23.19. With a market capitalization of about $1.26 billion, Cullinan Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~-0.01). Key stats such as the average daily volume over the past year has been around 835.11 thousand shares, in line with its 52-week average. Headquartered in Cambridge, MA, Cullinan Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Nadim Ahmed, the company employs approximately 109 people and listed since January 08, 2021. Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 19.08%, SMA50 31.65%, SMA200 70.92%). The stock’s 14-day RSI is 73.06 (overbought), while the ATR of 0.92 points to higher daily volatility. The stock remains currently trading near 52-week highs, trading 4.46% below its high and over 167.78% above its low. Average 10-day trading volume of 1.10 million shares is slightly above the 3-month average of 841.83 thousand, indicating heightened recent market interest.

Valuation Metrics

Cullinan Therapeutics, Inc. trades at a P/E ratio of -6.07, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.91 trading at moderately above to book value. The P/FCF stands at -7.89, also below market averages.

Dividend & Fair Value

Cullinan Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.45. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Cullinan Therapeutics, Inc. generated EPS of -$3.68 over the past year. Five-year average earnings growth is -45.66%. Wall Street analysts project EPS growth of -1.6% annually over the next five years. The latest quarter delivered EPS of -$0.81. The next quarter is forecast at -$0.81. Next year's EPS is expected at -$0.61. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 12 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $40.00 to $26.00. The high target offers 94.74% upside. The low target suggests 26.58% downside. The mean target is $34.44. This offers 67.67% upside. Cullinan Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 06, 2026, missed forecasts by 1.34%. The prior quarter beat by -10.27%. Over the last six quarters, Apple has recorded several small beats. These include -5.13% in May 08, 2025.

Shareholding & Insider Activity

Cullinan Therapeutics, Inc. has 61.46 million shares outstanding. The public float is 48.08 million shares, elevated short interest at 22.19% of float. This equals 10.25 million shares. The short ratio is 16.88 days. Institutional investors hold 108.28% of the float. Insiders own 0.45%. Lynx1 Capital Management LP holds 8.96 million shares, UBS Oncology Impact Fund L.P. has 7.65 million shares and LAMPERT MARK N has 4.06 million shares. Over the past six months, insider transactions show net selling. They sold 46.20 thousand shares across 4 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Cullinan Therapeutics has not generated any revenue. Returns are negative, with ROA at -31.57% and ROE at -33.76%.
On valuation metrics, Cullinan Therapeutics trades at a P/E of -6.07, P/S of 0.00 and P/B of 3.91. The current ratio is 8.42 and quick ratio is 8.42. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -76.90.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Cullinan Therapeutics posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $310.00K (margin 0.00%). Operating income was - $190.65M (margin 0.0%). Net income was- $153.16M (EPS - $3.69).
The company ended the quarter with $467.07M in cash and short-term investments, a total debt of $3.59M, and net debt of - $94.84M. Total assets were $485.10M, with equity of $453.90M. Financials further reflected weakness, with operating cash flow of - $134.28M, free cash flow of - $134.48M, and capital expenditures of - $208.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Cullinan Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.67%, with price expected at $19.58 by September 29, 2026, within a range of $18.80 to $20.45 3-Month Outlook: Projected rise of 98.49%, reaching $40.77 by December 11, 2026, with a range of $40.14 to $41.55. 1-Year Outlook: Projected gain of 1.85%, with price at $20.92 by September 15, 2027, within a range of $19.17 to $22.85.

Key Takeaways

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) shares are flat 5.02% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cullinan Therapeutics, Inc. trading at a premium to the broader market with a P/E of -6.07. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $35.68, suggesting 73.71% upside. Our AI forecast model points to short-term weakness (-4.67% over two weeks), a medium-term rise (98.49% over three months), and a longer-term gain (1.85% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Cullinan Therapeutics, Inc. (CGEM) stock price?

Cullinan Therapeutics, Inc. (NASDAQ: CGEM) stock price is $20.54 in the last trading session. During the trading session, CGEM stock reached the peak price of $20.70 while $19.64 was the lowest point it dropped to. The percentage change in CGEM stock occurred in the recent session was 0.69% while the dollar amount for the price change in CGEM stock was $0.14.

CGEM's industry and sector of operation?

The NASDAQ listed CGEM is part of Biotechnology industry that operates in the broader Healthcare sector. Cullinan Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CGEM?

Ms. Rose Weldon
Senior Vice President of Communications
Dr. Corinne Savill Ph.D.
Chief Bus. Officer
Mr. Nadim Ahmed
Pres, Chief Executive Officer & Director
Mr. Jeffrey Trigilio
Chief Financial Officer & Treasurer
Dr. Jennifer Michaelson Ph.D.
Chief Devel. Officer
Mr. Steve Andre
Chief HR Officer
Ms. Kerry Whalen
Senior Director of Preclinical & Early Devel.
Mr. Kevin A. Johnston
Chief Technical Operations Officer
Dr. Patrick A. Baeuerle Ph.D.
Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board
Dr. Jeffrey Jones M.B.A., M.D., M.P.H.
Chief Medical Officer
Ms. Jacquelyn L. Sumer J.D.
Chief Legal Officer, Chief Compliance Officer & Corporation Sec.

How CGEM did perform over past 52-week?

CGEM's closing price is 261.62% higher than its 52-week low of $5.68 where as its distance from 52-week high of $23.19 is -11.43%.

How many employees does CGEM have?

Number of CGEM employees currently stands at 109.

Link for CGEM official website?

Official Website of CGEM is: https://cullinantherapeutics.com

How do I contact CGEM?

CGEM could be contacted at phone 617 410 4650 and can also be accessed through its website. CGEM operates from One Main Street, Cambridge, MA 02142, United States.

How many shares of CGEM are traded daily?

CGEM stock volume for the day was 1.06M shares. The average number of CGEM shares traded daily for last 3 months was 835.11K.

What is the market cap of CGEM currently?

The market value of CGEM currently stands at $1.26B with its latest stock price at $20.54 and 61.46M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	109
Beta	-0.01
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CGEM Company Profile and Key Details

Cullinan Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook